Azernews.Az

Sunday July 14 2024

U.S. doctors reconsider Pfizer's Paxlovid for lower-risk COVID patients

30 May 2022 09:17 (UTC+04:00)
U.S. doctors reconsider Pfizer's Paxlovid for lower-risk COVID patients

By Trend

Use of Pfizer Inc's (PFE.N) COVID-19 antiviral Paxlovid spiked this week, but some doctors are reconsidering the pills for lower-risk patients after a U.S. public health agency warned that symptoms can recur after people complete a course of the drug, and that they should then isolate a second time, Trend reports citing Reuters.

More quarantine time "is not a crowd-pleaser," Dr. Sandra Kemmerly, an infectious disease specialist at Ochsner Health in New Orleans, told Reuters. "For those people who really aren't at risk ... I would recommend that they not take it."

Use of Pfizer's Paxlovid, authorized to treat newly infected, at-risk people in order to prevent severe illness, has soared as infections have risen. More than 162,000 courses were dispensed last week - compared with an average of 33,000 a week since the drug was launched late last year, according to government data. Biden administration officials have pushed for wide use of Paxlovid, which the government purchased and provides free.

But higher use has also come with more reports from people who say their symptoms eased with Paxlovid only to return a few days after finishing a five-day regimen of the pills.

--

Follow us on Twitter @AzerNewsAz

Loading...
Latest See more